European Legislative Bodies Consent on the Proposed Regulations:

European Legislative Bodies Consent on the Proposed Regulations:

In the heart of Magdeburg, Germany, Auditorium 1 of the main campus at Building 26 (near the university library), Pfälzer Straße, played host to an enlightening event on August 17, 2025. The Medical Sunday, a collaboration between Urania Magdeburg e.V., Volksstimme, and the University Medicine Magdeburg, offered a captivating exploration into numerous medical topics, with a particular focus on "From Immunotherapy to Theranostics: Precision Medicine in Modern Cancer Treatment".

The event featured Prof. Dr. med. Dimitrios Mougiakakos and Prof. Dr. med. Michael Kreißl as speakers. Prof. Mougiakakos, the Director of the University Clinic for Hematology, Oncology, and Cell Therapy Magdeburg, has been working in the field of blood and lymphatic cancer for over 15 years. Prof. Kreißl, the Head of Nuclear Medicine at the University Medicine Magdeburg and the Spokesman of the Thyroid Section of the German Society for Endocrinology, shared valuable insights into the latest developments in precision medicine.

The presentations by Professors Mougiakakos and Kreißl highlighted current procedures, innovative techniques, and gentle methods in precision medicine for modern cancer treatment, particularly focusing on immunotherapy and theranostics. These approaches emphasize personalized, targeted, and less invasive approaches to combat cancer.

One of the key points discussed was the integration of precision immunotherapy advancements. Utilizing biomarker-guided approaches, such as antibody-drug conjugates (ADCs) and small molecule targeted therapies, these methods precisely target tumor cells with minimal damage to healthy tissue, enhancing efficacy and reducing side effects.

Theranostics, the strategic combination of diagnostic imaging with therapeutic radionuclides for precise localization and effective combat of abnormal cells in cancer treatment, was another topic of interest. This integration allows for real-time monitoring and treatment of cancers, employing molecular insights to adapt treatment dynamically, improving patient-specific outcomes.

Innovative delivery methods, such as nanotechnology, were also discussed. Nanoparticles, liposomes, solid lipid nanoparticles, and polymeric carriers are used to enhance drug delivery precision, bioavailability, and reduce systemic toxicity. For example, nanoformulations of drugs like imatinib are being developed for advanced cancer therapy.

The event also touched upon multi-omics and data integration. By incorporating genomics, proteomics, metabolomics, and other molecular data, patient stratification and therapy customization can be refined, thereby improving treatment responses and minimizing adverse effects.

The speakers also emphasized the importance of gentle and patient-friendly techniques. These methods focus on reducing treatment-related side effects and improving quality of life by leveraging less invasive immunological treatments and biomarker-driven interventions, often enabling outpatient protocols and minimizing surgical interventions.

Lastly, the role of artificial intelligence in precision oncology was explored. AI is being employed to predict drug responses and optimize therapy plans, accelerating drug discovery and facilitating personalized treatments with fewer side effects.

This holistic approach, where precision medicine merges immunotherapy and theranostics with innovative, gentle technologies, is creating highly personalized and effective cancer treatments. The Medical Sunday presentations by Professors Mougiakakos and Kreißl underscored the University Medicine Magdeburg's commitment to advancing cancer treatment through cutting-edge research and practice.

Admission to the event was free, making it accessible to a wide audience interested in understanding the latest advancements in precision oncology. The University Medicine Magdeburg's specialized stationary area for stem cell transplantation and CAR-T cell therapy, which holds the internationally recognized JACIE quality seal, further demonstrates its commitment to providing world-class cancer care.

Whether battling leukemia, a type of blood cancer that affects the blood-forming and lymphatic system, or other common oncological diseases such as tumors of the lung, breast, prostate, thyroid, and hematological cancers like leukemias and lymphomas, the future of cancer treatment is promising. With advancements in precision medicine, the fight against cancer is becoming more targeted, personalized, and effective.

1. Evident at the Medical Sunday event in Magdeburg, Germany, a focus on precision medicine in the treatment of chronic diseases like cancer, particularly through immunotherapy and theranostics, is leading to more targeted, personalized, and less invasive approaches.
2. The discussions centered around innovative therapies and treatments, such as nanotechnology and artificial intelligence, which aim to enhance drug delivery precision, bioavailability, and reduce systemic toxicity in cancer treatment, particularly for leukemia and other oncological diseases.
3. The integration of cutting-edge research and practice in precision oncology, emphasizing gentle methods, data integration, and artificial intelligence, is promising for the future, making cancer treatment more effective and accessible for a wider audience.

Read also: